Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma
Pauline Tétu(Inserm), Célèste Lebbé(Inserm), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Nicolás Meyer(Université Toulouse III - Paul Sabatier), Stéphane Dalle(Mount Sinai Hospital), Joanna Mangana(University Hospital of Zurich), Reinhard Dummer(University of Zurich), Bastien Oriano(Hôtel-Dieu de Paris), N. Bénéton(Centre Hospitalier du Mans), Olivier Michielin(SIB Swiss Institute of Bioinformatics)
Cited by 14
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k